Gabrielle T Maldonado
Overview
Explore the profile of Gabrielle T Maldonado including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
15
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bono R, White A, Imran R, Maldonado G, Lipato T, Barnes A, et al.
Drug Alcohol Depend
. 2024 Dec;
266():112508.
PMID: 39657440
Introduction: Electronic nicotine delivery system (ENDS) product standards for nicotine flux (nicotine emitted/second), combined with limiting puff duration, could control nicotine dose and support ENDS regulations. We assessed behavioral and...
2.
Patev A, Maldonado G, Sawyer-Mays A, Cobb C, Breland A
Subst Use Misuse
. 2024 Nov;
60(2):211-218.
PMID: 39523921
Sexual and gender minority (SGM) individuals report rates of tobacco use that range from 19% to 40% compared to roughly 20% of the general population. Higher rates of tobacco use,...
3.
Maldonado G, Hochsmann C, Anbil A, Neubig K, Imran R, Fuemmeler B, et al.
Exp Clin Psychopharmacol
. 2024 Feb;
32(4):465-474.
PMID: 38358733
Previous work has aimed to disentangle the acute effects of nicotine and smoking on appetite with mixed findings. Electronic nicotine delivery systems (ENDS) have yet to be examined in this...
4.
Maldonado G, Bono R, Wall C, Lester R, Hoetger C, Blankenship M, et al.
Exp Clin Psychopharmacol
. 2023 Jan;
31(4):817-828.
PMID: 36656717
The U.S. Food and Drug Administration proposed new product standards that would ban characterizing flavors (other than tobacco) in cigars. To inform this regulatory action, we compared physiological effects, use...
5.
Manzanares M, Campbell D, Maldonado G, Sirica A
Hepatol Commun
. 2018 Feb;
2(2):155-172.
PMID: 29404524
Periostin and mesothelin have each been suggested to be predictors of poor survival for patients with intrahepatic cholangiocarcinoma, although the clinical prognostic value of both of these biomarkers remains uncertain....
6.
Manzanares M, Usui A, Campbell D, Dumur C, Maldonado G, Fausther M, et al.
Am J Pathol
. 2017 Mar;
187(5):1068-1092.
PMID: 28315313
To gain insight into the cellular and molecular interactions mediating the desmoplastic reaction and aggressive malignancy of mass-forming intrahepatic cholangiocarcinoma (ICC), we modeled ICC desmoplasia and progression in vitro. A...